TY - JOUR AU - Nádas, Orsolya Erzsébet AU - Fügei, Éva AU - Kordáné Horváth, Orsolya TI - Hozzátartozókat Támogató Klub az Országos Onkológiai Intézetben JF - ORVOSI KÖNYVTÁRAK J2 - ORVOSI KÖNYVTÁRAK VL - 64 PY - 2024 IS - 1 SP - 41 EP - 41 PG - 1 SN - 2061-036X UR - https://m2.mtmt.hu/api/publication/34793269 ID - 34793269 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Kordáné Horváth, Orsolya AU - Kovács, Péter TI - A korszerű szupportív ellátás és az integrált korai palliatív gondozás jelentősége és fontosabb területei agydaganatos betegek kezelése során JF - MAGYAR ONKOLÓGIA J2 - MAGYAR ONKOLÓGIA VL - 68 PY - 2024 IS - 1 SP - 77 EP - 85 PG - 9 SN - 0025-0244 UR - https://m2.mtmt.hu/api/publication/34756803 ID - 34756803 LA - Hungarian DB - MTMT ER - TY - GEN AU - Kordáné Horváth, Orsolya TI - Daganatos betegek palliatív kezelése PY - 2024 UR - https://m2.mtmt.hu/api/publication/34685827 ID - 34685827 N1 - Előadás LA - Hungarian DB - MTMT ER - TY - JOUR AU - Kovács, Péter AU - Kordáné Horváth, Orsolya TI - Az onkopszichológiai ellátás hazai gyakorlata: keretek, irányelvek, lehetőségek JF - MAGYAR ONKOLÓGIA J2 - MAGYAR ONKOLÓGIA VL - 67 PY - 2023 IS - 1. szuppl. SP - 39 EP - 39 PG - 1 SN - 0025-0244 UR - https://m2.mtmt.hu/api/publication/34343034 ID - 34343034 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Váradi, Melinda AU - Kordáné Horváth, Orsolya AU - Módos, Orsolya AU - Fazekas, Tamás AU - Grunewald, Camilla M AU - Niegisch, Günter AU - Krafft, Ulrich AU - Grünwald, Viktor AU - Hadaschik, Boris AU - Oláh, Csilla AU - Maráz, Anikó AU - Furka, Andrea AU - Szűcs, Miklós AU - Nyirády, Péter AU - Szarvas, Tibor TI - Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study JF - SCIENTIFIC REPORTS J2 - SCI REP VL - 13 PY - 2023 IS - 1 PG - 11 SN - 2045-2322 DO - 10.1038/s41598-023-44103-9 UR - https://m2.mtmt.hu/api/publication/34199654 ID - 34199654 AB - Clinical trials revealed significant antitumor activity for immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC). Due to their strict eligibility criteria, clinical trials include selected patient cohorts, and thus do not necessarily represent real-world population outcomes. In this multicentric, retrospective study, we investigated real-world data to assess the effectiveness of pembrolizumab and atezolizumab and to evaluate the prognostic value of routinely available clinicopathological and laboratory parameters. Clinical and follow-up data from mUC patients who received ICIs (01/2017-12/2021) were evaluated. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and duration of response (DOR) were used as endpoints. Patients' (n = 210, n = 76 atezolizumab and 134 pembrolizumab) median OS and PFS were 13.6 and 5.9 months, respectively. Impaired ECOG-PS, the presence of visceral, liver or bone metastases, and hemoglobin levels were independently associated with poor OS and DCR. Furthermore, Bellmunt risk factors and the enhanced Bellmunt-CRP score were shown to be prognostic for OS, PFS and DCR. In conclusion, ICIs are effective treatments for a broad range of mUC patients. Our results confirmed the prognostic value of numerous risk factors and showed that Bellmunt risk scores can further be improved when adding CRP to the model. LA - English DB - MTMT ER - TY - GEN AU - Kordáné Horváth, Orsolya TI - Szunitinib kezelés aktualitásai, betegedukáció jelentősége a mellékhatások menedzselésében PY - 2023 UR - https://m2.mtmt.hu/api/publication/34126580 ID - 34126580 LA - Hungarian DB - MTMT ER - TY - GEN AU - Kordáné Horváth, Orsolya TI - Daganatos betegek palliatív kezelése PY - 2023 UR - https://m2.mtmt.hu/api/publication/33653457 ID - 33653457 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Széles, Ádám Dániel AU - Kovács, Petra Terézia AU - Pásztor-Csizmarik, Anita AU - Váradi, Melinda AU - Riesz, Péter AU - Fazekas, Tamás AU - Váncsa, Szilárd AU - Hegyi, Péter AU - Oláh, Csilla AU - Tschirdewahn, Stephan AU - Darr, Christopher AU - Krafft, Ulrich AU - Grünwald, Viktor AU - Hadaschik, Boris AU - Kordáné Horváth, Orsolya AU - Nyirády, Péter AU - Szarvas, Tibor TI - High Pretreatment Serum PD-L1 Levels Are Associated with Muscle Invasion and Shorter Survival in Upper Tract Urothelial Carcinoma JF - BIOMEDICINES J2 - BIOMEDICINES VL - 10 PY - 2022 IS - 10 PG - 12 SN - 2227-9059 DO - 10.3390/biomedicines10102560 UR - https://m2.mtmt.hu/api/publication/33198986 ID - 33198986 N1 - Department of Urology, Semmelweis University, Ulloi ut 78/b, Budapest, 1082, Hungary Centre for Translational Medicine, Ulloi ut 26, Budapest, 1085, Hungary Institute for Translational Medicine, Medical School, University of Pécs, Szigeti út 12, Pécs, 7624, Hungary Division of Pancreatic Diseases, Heart and Vascular Center, Semmelweis University, Budapest, 1085, Hungary Department of Urology, University of Duisburg-Essen, German Cancer Consortium (DTKK)-University Hospital Essen, Hufelandstraße 55, Essen, D-45147, Germany Department of Genitorurinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Ráth György utca 7-9., Budapest, 1122, Hungary Export Date: 17 January 2024 Correspondence Address: Szarvas, T.; Department of Urology, Ulloi ut 78/b, Hungary; email: szarvas.tibor@med.semmelweis-univ.hu AB - Programmed death ligand-1 (PD-L1) is an immune checkpoint molecule and a widely used therapeutic target in urothelial cancer. Its circulating, soluble levels (sPD-L1) were recently suggested to be associated with the presence and prognosis of various malignancies but have not yet been investigated in upper tract urothelial carcinoma (UTUC). In this study, we assessed sPD-L1 levels in 97 prospectively collected serum samples from 61 UTUC patients who underwent radical nephroureterectomy (RNU), chemotherapy (CTX), or immune checkpoint inhibitor (ICI) therapy. In addition to pretreatment samples, postoperative and on-treatment sPD-L1 levels were determined in some patients by using ELISA. In the RNU group, elevated preoperative sPD-L1 was associated with a higher tumor grade (p = 0.019), stage (p < 0.001) and the presence of metastasis (p = 0.002). High sPD-L1 levels were significantly associated with worse survival in both the RNU and CTX cohorts. sPD-L1 levels were significantly elevated in postoperative samples (p = 0.011), while they remained unchanged during CTX. Interestingly, ICI treatment caused a strong, 25-fold increase in sPD-L1 (p < 0.001). Our results suggest that elevated preoperative sPD-L1 level is a predictor of higher pathological tumor stage and worse survival in UTUC, which therefore may help to optimize therapeutic decision-making. The observed characteristic sPD-L1 flare during immune checkpoint inhibitor therapy may have clinical significance. LA - English DB - MTMT ER - TY - JOUR AU - Kordáné Horváth, Orsolya AU - Rácz, Katalin AU - Jakus, Nikoletta AU - Kegye, Adrienne AU - Hegedűs, Katalin TI - A hospice-palliatív ellátás hatékony integrálása a hazai onkológiai és családorvosi gyakorlatba JF - ORVOSI HETILAP J2 - ORV HETIL VL - 163 PY - 2022 IS - 38 SP - 1520 EP - 1527 PG - 8 SN - 0030-6002 DO - 10.1556/650.2022.32561 UR - https://m2.mtmt.hu/api/publication/33094240 ID - 33094240 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Kovács, Péter AU - Kordáné Horváth, Orsolya TI - A komplex onkopszichológiai ellátás gyakorlata az Országos Onkológiai Intézetben JF - MAGYAR ONKOLÓGIA J2 - MAGYAR ONKOLÓGIA VL - 65 PY - 2021 IS - 1 SP - 34 EP - 34 PG - 1 SN - 0025-0244 UR - https://m2.mtmt.hu/api/publication/32541121 ID - 32541121 LA - Hungarian DB - MTMT ER -